Srinagar: With another spike in COVID infections, India on Thursday witnessed 56,282 new cases, pushing the country’s tally to 19,64,536.
According to a report by the Health Ministry of India, there are 5,95,501 active cases in the country and 13,28,336 patients have been discharged.
The number of fatalities has reached 40,699 after 904 deaths were reported in the last 24 hours.
In India, the total number of testing of COVID samples has reached 2.21 crore, out of which 6,64,949 samples were tested on Wednesday.
On Wednesday, India saw its recovery rate rise to 67.19 per cent after 51,706 patients recuperated from the deadly disease, the health ministry report said, adding the case fatality rate has further dropped to 2.09 per cent.
Meanwhile, pharmaceutical company Zydus Cadila has said that it will start phase 2 clinical trials to establish the efficacy of the COVID vaccine candidate from July 7, 2020.
On July 25, a week after the All India Institute of Medical Sciences (AIIMS) gave its approval for conducting the human clinical trial of the COVID vaccine, a 30-year-old man was given the dose of under trial vaccine Covaxin.
Around 12 volunteers were called for a number of pre-tests that include blood and nasopharyngeal testing for the deadly coronavirus.
Soon after the results were found, 10 healthy individuals were selected for the vaccine to be given in phases and their health condition will be submitted to the ethics committee of AIIMS, which will review the entire process.
Free Press Kashmir is now on Telegram. Click here to Join.